Who makes aspirin® , clopidogrel® , atorvastatin®?

aspirin® , clopidogrel® , atorvastatin® is developed by Xuanwu Hospital, Beijing.

What development phase is aspirin® , clopidogrel® , atorvastatin® in?

aspirin® , clopidogrel® , atorvastatin® is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

aspirin® , clopidogrel® , atorvastatin®

Xuanwu Hospital, Beijing · FDA-approved active Small molecule Quality 0/100

Aspirin®, clopidogrel®, and atorvastatin® are marketed drugs developed by Xuanwu Hospital, Beijing, with a key composition patent expiring in 2028. The primary strength of these drugs lies in their well-established market presence and broad therapeutic applications. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic name	aspirin® , clopidogrel® , atorvastatin®
Sponsor	Xuanwu Hospital, Beijing
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Evaluation Of HUK in Acute Stroke Patients: MRS and CTP (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

aspirin® , clopidogrel® , atorvastatin® CI brief — competitive landscape report
aspirin® , clopidogrel® , atorvastatin® updates RSS · CI watch RSS
Xuanwu Hospital, Beijing portfolio CI